Search Results - "Cutitar, M."

Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study by Lopresti, M. L., Bian, J. J., Sakr, B. J., Strenger, R. S., Legare, R. D., Fenton, M., Witherby, S. M., Dizon, D. S., Pandya, S. V., Stuckey, A. R., Edmondson, D. A., Gass, J. S., Emmick, C. M., Graves, T. A., Cutitar, M., Olszewski, A. J., Sikov, W. M.

“…Purpose In HER2-positive breast cancer (HER2+ BC), neoadjuvant chemotherapy (NACT) with dual HER2-targeted therapy achieves high pathologic complete response…”
Get full text

Perforated peptic ulcer. Determinants of morbidity and mortality by Koness, R J, Cutitar, M, Burchard, K W

“…A review of 109 patients with perforated peptic ulcer revealed a sex ratio of 60:49, male:female, with mean age of 67 (76 patients greater than or equal to age…”
Get more information